Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer

Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer

Second‐line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour‐derived DNA (ctDNA) levels may guide patient stratification, provided that an affordable and robust assay is available. Here, we investigate...

Full description

Bibliographic Details
Main Authors: Pauline A. J. Mendelaar, Debbie G. J. Robbrecht, Maud Rijnders, Ronald deWit, Vanja deWeerd, Teoman Deger, Hans M. Westgeest, Maureen J. B. Aarts, Jens Voortman, John W. M. Martens, Astrid A. M. van derVeldt, José Alberto Nakauma‐González, Saskia M. Wilting, Martijn Lolkema
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Molecular Oncology
Subjects:
advanced urothelial carcinoma
biomarker
chromosomal instability
ctDNA
liquid biopsies
pembrolizumab
Online Access:https://doi.org/10.1002/1878-0261.13196

Internet

https://doi.org/10.1002/1878-0261.13196

Similar Items